Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Taiwan May End Free HIV/AIDS Medication To Trim CDC Budget Shortfall

This article was originally published in PharmAsia News

Executive Summary

Taiwan may end a decade-long program of providing free AIDS drugs, citing rising costs as life expectancy grows.

You may also be interested in...

Pricing Pressures Intensify In Asia As Healthcare Budget Battles Rage On

HONG KONG - Pharmacies and hospitals in the Philippines had until Tuesday to halve prices of a range of drugs or face the wrath of regulators keen to lower drug prices

Taiwan, Japan Eye Drug Regulation Streamlining To Curb Costs

Regulators from Japan and Taiwan met in late December to review prospects for convergence and pointed to manufacturing and new drug approvals as areas that were ripe for harmonization agreements.

Taiwan Looks To Generic Savings In HIV Drug Reimbursement To Build On Multinational Price Cuts

Following an agreement by six multinational firms – including GlaxoSmithKline and AbbVie – to cut prices for antiretrovirals, Taiwan’s Centers for Disease Control is looking to import generic drugs for its free HIV drug reimbursement program, which has met with success only to see costs explode.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts